All news

News

GLP-1s cut cancer risk compared to insulin — but benefits vary by diabetes severity

A new JAMA Network Open study reveals GLP-1s lower obesity-related cancer risk compared to insulin, with the greatest benefit seen in low-severity patients.

By CompareRx Editorial Team · Medically reviewed by CompareRx Medical Review Desk
Published
A clinical researcher reviewing oncology data on a tablet next to a GLP-1 medication pen.

Key takeaways

  • A new JAMA Network Open study found GLP-1s are associated with a lower risk of obesity-related cancers compared to insulin and sulfonylureas.
  • The preventative cancer benefit of GLP-1s was most pronounced in patients with low-severity, early-stage diabetes.
  • No significant difference in cancer risk was found when comparing GLP-1s to metformin, DPP-4 inhibitors, or SGLT2 inhibitors.

Compare providers side by side or read the full GLP-1 guides.

Key takeaways

  • A new JAMA Network Open study found GLP-1s are associated with a lower risk of obesity-related cancers compared to insulin and sulfonylureas.
  • The preventative cancer benefit of GLP-1s was most pronounced in patients with low-severity, early-stage diabetes.
  • No significant difference in cancer risk was found when comparing GLP-1s to metformin, DPP-4 inhibitors, or SGLT2 inhibitors.
  • The data aligns closely with the typical preventative health profile of cash-pay telehealth GLP-1 buyers.

What happened

A large retrospective cohort study published in JAMA Network Open has revealed that GLP-1 receptor agonists are associated with a significantly lower risk of obesity-related cancers compared to insulin and sulfonylureas. However, this preventative benefit varies widely by patient health profile, with the most pronounced cancer-risk reductions occurring in patients with milder, low-severity diabetes.

Why it matters

This study, conducted by researchers at UT Southwestern Medical Center, offers crucial clinical context for the millions of Americans purchasing GLP-1 medications out-of-pocket through online telehealth platforms. Patients utilizing cash-pay telehealth providers often have lower-severity metabolic profiles, typically seeking treatment for obesity or early-stage type 2 diabetes rather than advanced, insulin-dependent diabetes. The data suggests that this specific demographic—the typical preventative healthcare consumer—stands to gain the most significant long-term cancer-prevention benefits from GLP-1 therapy compared to older-generation diabetes treatments.

What the data says

Using PCORnet electronic health record data, researchers analyzed 359,595 adults with type 2 diabetes treated between January 2010 and July 2025. The study examined the incidence of obesity-related cancers (ORCs) at three-year and five-year intervals after patients initiated treatment with GLP-1 receptor agonists compared to five other classes of diabetes medications.

The data revealed distinct differences based on the comparative medication and diabetes severity:

  • GLP-1s vs. Insulin: At the 3-year mark, GLP-1 users had an estimated ORC risk of 2.01%, compared to 3.26% for those on insulin.
  • GLP-1s vs. Sulfonylureas: GLP-1 users had a 2.85% estimated ORC risk at 3 years, compared to 3.98% for patients taking sulfonylureas.
  • Other Medications: The risk of ORCs for GLP-1 users did not differ significantly when compared to patients taking metformin, DPP-4 inhibitors, or SGLT2 inhibitors. In fact, patients with moderate- to high-severity diabetes actually fared better with SGLT2 inhibitors during the first three years of treatment.
  • The Severity Factor: The comparative benefit of GLP-1s over insulin and sulfonylureas was most pronounced in patients categorized as having "low-severity" diabetes (determined by a lack of pre-existing complications like advanced kidney disease or macrovascular disease). At 5 years, the risk differences still favored GLP-1 drugs over insulin and sulfonylureas across almost all severity categories.

Lead study author Jesús Gibran Hernández-Pérez, PhD, cautioned that the retrospective data "do not establish that GLP-1 receptor agonists prevent cancer or that insulin or sulfonylureas cause cancer." Instead, they highlight how a patient's underlying health status and treatment history dictate these clinical outcomes.

How it compares

For cash-paying consumers comparing GLP-1 options on online telehealth platforms, these findings add a layer of preventative value to the financial equation. While older medications like metformin and sulfonylureas are highly affordable—often costing under $10 a month—they do not offer the same weight-loss or cardiovascular protection as brand-name GLP-1s like Ozempic, Wegovy, or Zepbound.

Currently, brand-name GLP-1 medications carry retail prices ranging from $900 to $1,350 per month without insurance. For patients who do not meet strict coverage criteria, clinical telehealth platforms have populated the market with compounded semaglutide and compounded tirzepatide options, which generally range from $200 to $400 per month. When comparing the long-term value of these clinical programs, buyers often look beyond immediate weight loss. This data suggests that for patients with milder metabolic issues, paying the premium for a GLP-1 program over cheap first-line therapies like sulfonylureas may yield substantial, secondary cancer-preventative advantages.

How this fits the bigger picture

This study builds on a growing body of clinical evidence linking weight-loss medications to broad, systemic health improvements that extend far beyond the scale. For instance, a previous study highlighted in our coverage of obesity in young adults and early-onset cancer risk established a clear link between early-life visceral fat and a spike in early-onset cancers, solidifying the preventative case for early GLP-1 intervention.

This trend of discovering secondary therapeutic benefits is reshaping how consumers evaluate GLP-1 therapy. For example, clinical trials have recently demonstrated how these medications can address other complex systemic issues, such as how tirzepatide improves menstrual regularity in PCOS patients. As the clinical literature expands, telehealth patients are increasingly viewing GLP-1s not as short-term cosmetic tools, but as foundational, preventative healthcare investments.

What happens next

While these retrospective findings are encouraging, researchers emphasize that treatment decisions should still be driven by established metabolic, cardiovascular, and renal guidelines rather than cancer prevention alone. Prospective, randomized controlled trials will be necessary to definitively prove whether GLP-1 receptor agonists exert a direct, protective anti-tumor effect or if the reduced cancer risk is simply a byproduct of substantial weight loss and improved glycemic control.

In the meantime, the data provides valuable reassurance to early-stage metabolic patients utilizing cash-pay platforms to manage their health proactively.

Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication regimen.

Find the provider that fits your budget

Compare 100+ online GLP-1 providers on true monthly cost, or get your top 3 matches in 90 seconds.

More from the newsroom

Popular comparisons

Sources

Community

What do you make of this?

Add your take, ask a question, or tell us what you're seeing with your own provider — our editors read every thread.

Medical disclaimer: CompareRx.org is an independent comparison site and publisher. This article is informational only, is not medical advice, and is not a substitute for care from a licensed clinician. Read our medical disclaimer, editorial policy and affiliate disclosure.